MET as a target for treatment of chest tumors.

  title={MET as a target for treatment of chest tumors.},
  author={Nicole A Cipriani and Oyewale O. Abidoye and Everett E. Vokes and Ravi Salgia},
  journal={Lung cancer},
  volume={63 2},
The receptor tyrosine kinase MET has been studied of a large variety of human cancers, including lung and mesothelioma. The MET receptor and its ligand HGF (hepatocyte growth factor) play important roles in cell growth, survival and migration, and dysregulation of the HGF-MET pathway leads to oncogenic changes including tumor proliferation, angiogenesis and metastasis. In small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), and malignant pleural mesothelioma (MPM), MET is… CONTINUE READING
45 Citations
150 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 45 extracted citations


Publications referenced by this paper.
Showing 1-10 of 150 references

, ThunMJ . Cancer statistics

  • R Siegel, E Ward, T Murray, J Xu
  • CA Cancer J Clin
  • 2007

A phase 2 study of the dual MET / VEGFR 2 inhibitor XL 880 in patients ( pts ) with papillary renal carcinoma ( PRC )

  • R Ross, VaishampayanU SrinivasanR, R Bukowski, J Rosenberg, P Eisenberg
  • 2007

A phase I dose escalation study of the safety and pharmacokinetics ( PK ) of XL 184 , a VEGFR andMET kinase inhibitor , administered orally to patients ( pts ) with advanced malignancies

  • R Salgia, D Hong, S Sherman, C Ng, J Frye, L Janisch
  • 2007

A phase II study of the c - Met RTK inhibitor XL 880 inpatients ( pts ) with papillary renalcell carcinoma ( PRC )

  • RW Ross, M Stein, J Sarantopoulos, P Eisenberg, T Logan, S Srinivas
  • J Clin Oncol
  • 2007

Similar Papers

Loading similar papers…